These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33653187)

  • 1. Accelerating Alzheimer's disease drug discovery and development: what's the way forward?
    Imbimbo BP; Ippati S; Watling M; Balducci C
    Expert Opin Drug Discov; 2021 Jul; 16(7):727-735. PubMed ID: 33653187
    [No Abstract]   [Full Text] [Related]  

  • 2. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?
    Imbimbo BP; Ippati S; Watling M
    Expert Opin Drug Discov; 2020 Nov; 15(11):1241-1251. PubMed ID: 32686970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What have we learned from past failures of investigational drugs for Alzheimer's disease?
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1175-1182. PubMed ID: 34890262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.
    Boxer AL; Sperling R
    Cell; 2023 Oct; 186(22):4757-4772. PubMed ID: 37848035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
    Mullane K; Williams M
    Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update.
    Bales KR
    Expert Opin Drug Discov; 2012 Apr; 7(4):281-97. PubMed ID: 22458501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
    Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
    Elife; 2020 Mar; 9():. PubMed ID: 32228858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.
    Abeysinghe AADT; Deshapriya RDUS; Udawatte C
    Life Sci; 2020 Sep; 256():117996. PubMed ID: 32585249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?
    Cacabelos R
    Expert Opin Drug Discov; 2018 Jun; 13(6):523-538. PubMed ID: 29607687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on pharmacotherapy of Alzheimer's disease.
    Chopra K; Misra S; Kuhad A
    Expert Opin Pharmacother; 2011 Feb; 12(3):335-50. PubMed ID: 21222549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
    Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
    Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.